Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: juvenile idiopathic arthritis

Get Excited for ACR Convergence 2024

  |  

An engaging mix of new and returning programming is planned for ACR Convergence in Washington, D.C. “ACR Convergence is unique because of the blend of high-quality science, updates on advances in clinical care and networking opportunities to advance the field of rheumatology,” says Annual Meeting Planning Committee (AMPC) Chair Gregory C. Gardner, MD, MACP. “We…

The Impact of Climate Change

  |  

Although research is still emerging, evidence suggests changes in climate, such as increases in heat, pollution and allergens, may increase the risk of flare and hospitalization in patients with rheumatoid arthritis, systemic lupus erythematosus and other rheumatic conditions. Paul Dellaripa, MD, discussed the research and how rheumatologists can help their patients.

Dual Certification: Med-Peds Rheumatology Is a Small, but Growing, Specialty

Sarah D. Bayefsky, MD  |  

Wondering how best to care for an adult patient with juvenile idiopathic arthritis-associated uveitis or a pediatric patient with early-onset osteoarthritis? Unsure how to manage a 23-year-old with chronic nonbacterial osteomyelitis or an 8-year-old with tophaceous gout due to Lesch-Nyhan syndrome? Ask a Med-Peds rheumatologist. What Is a Med-Peds Rheumatologist? Med-Peds rheumatologists in the U.S….

When Rheumatologists Have Rheumatic Diseases

  |  

  “I think we learn from medicine everywhere that it is, at its heart, a human endeavor, requiring good science but also a limitless curiosity and interest in your fellow human being, and that the physician-patient relationship is key; all else follows from it.”1 These profound words from Abraham Verghese, MD, MACP, Linda R. Meier…

FDA Approves Tocilizumab Biosimilar; Plus New Lupus Drug in Early Trials

  |  

The FDA has approved tocilizumab-aazg (Tyenne), the first tocilizumab biosimilar, for treating rheumatic diseases, as well as the new drug application for CB-101, a chimeric antigen receptor T cell therapy, for treating lupus nephritis and extra-renal lupus.

How to Effectively Diagnose & Treat Macrophage Activation Syndrome

  |  

“As a resident, [I] felt pretty terrible when [we had] a very sick child and the teams [couldn’t] agree on what to do,” said Lauren Henderson, MD, MMS, on an episode of ACR on Air. She discussed the importance of collaboration across specialties in the identification and treatment of macrophage activation syndrome (MAS).

Case Report: Complicated Presentation Eventually Explained by Rare Syndrome

Geoffrey E. Thiele, MD, & Iris Reyhan, MD  |  

Pachydermoperiostosis (PDP), also known as Touraine-Solente-Golé syndrome or primary hypertrophic osteoarthropathy, is a rare syndrome that can be inherited as autosomal dominant, autosomal recessive, or sporadically. This progressive disease primarily affects males, who tend to have more severe features than females. PDP usually occurs during adolescence, often starting around puberty.1 The main clinical features are…

Pharmacokinetic Modeling & Efficacy Extrapolation: FDA Takes New Approaches to Drug Approvals

  |  

An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.

Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology

  |  

SAN DIEGO—At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.